New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 10, 2012
07:02 EDTLHMitomics announces U.S. sales and marketing agreement with LabCorp
Mitomics announced an agreement with Laboratory Corporation. Under the agreement, urologists will be able to order Mitomics' flagship laboratory test, the Prostate Core Mitomic Test, through DIANON Systems.
News For LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
08:53 EDTLHLabCorp has a conference call hosted by JPMorgan
Subscribe for More Information
March 24, 2015
08:30 EDTLHLabCorp shares should be bought at current levels, says Maxim
Subscribe for More Information
07:46 EDTLHLabCorp price target raised to $160 from $141 at Maxim
Subscribe for More Information
March 12, 2015
08:48 EDTLHLabCorp announces new findings on HIV-1 and HCV antiviral drug resistance
Laboratory Corporation of America Holdings announced that Monogram Biosciences, a member of the LabCorp Specialty Testing Group, presented two new studies characterizing HIV-1 and HCV antiviral drug resistance at the 2015 Conference on Retroviruses and Opportunistic Infections. In a study entitled "Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1 Integrase," Monogram investigators demonstrate that resistance to dolutegravir, the newest member of the HIV-1 integrase inhibitor drug class, requires combinations of mutations known to confer resistance to this drug class. Using Monogramís proprietary PhenoSense HIV drug resistance platform, the investigators associate quantitative reductions in dolutegravir sensitivity with specific combinations of mutations that confer integrase inhibitor resistance. This finding supports the favorable response rates observed in patient populations treated with regimens that incorporate dolutegravir following prior treatment failure with an integrase inhibitorĖcontaining regimen. In a study entitled "Characterization of Naturally Occurring Resistance to HCV NS5A Inhibitors," Monogram investigators study the viruses of treatment naÔve individuals infected with HCV genotype 1 for the presence of mutations that are associated with NS5A inhibitor resistance. Using Monogramís proprietary HCV GenoSure NS5A Assay and a sensitive next generation sequencing approach, the investigators are able to detect pre-existing resistant variants within patient virus populations belonging to the two major HCV subtypes that circulate in the U.S. In addition, the investigators demonstrate that the size of the subpopulations of resistant variants within GT1a viruses is larger compared to GT1b viruses. Finally, using Monogramís proprietary PhenoSense HCV drug resistance assay, the investigators demonstrate that NS5A mutations confer larger reductions in NS5A inhibitor susceptibility in the context of GT1a sequences compared to GT1b sequences. Overall, these observations suggest that GT1a viruses may be more prone to naturally-occurring and acquired NS5A inhibitor resistance than GT1b viruses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use